Axel Hauschild Selected Research

Interferon alpha-2 (Roferon-A)

8/2021	Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma.
5/2018	The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.
11/2016	Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.
12/2015	Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
1/2013	Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
8/2009	Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.
7/2009	Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
7/2008	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
8/2003	Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Axel Hauschild Research Topics

Disease

151	Melanoma (Melanoma, Malignant) 11/2022 - 02/2003
55	Neoplasms (Cancer) 01/2022 - 01/2005
25	Neoplasm Metastasis (Metastasis) 10/2021 - 02/2003
13	Basal Cell Carcinoma (Rodent Ulcer) 01/2021 - 11/2002
10	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 06/2011
9	Disease Progression 01/2021 - 08/2006
8	Exanthema (Rash) 11/2021 - 03/2011
6	Brain Neoplasms (Brain Tumor) 01/2021 - 02/2008
6	Fatigue 10/2018 - 07/2008
5	Skin Neoplasms (Skin Cancer) 10/2021 - 10/2005
4	Fever (Fevers) 11/2021 - 07/2012
4	Lymphatic Metastasis 01/2021 - 08/2003
4	Diarrhea 10/2018 - 06/2009
4	Body Weight (Weight, Body) 01/2018 - 06/2011
4	Neutropenia 07/2014 - 07/2012
3	Merkel Cell Carcinoma 07/2018 - 01/2017
3	Keratoacanthoma 01/2015 - 06/2011
3	Alopecia (Baldness) 07/2014 - 10/2008
3	Arthralgia (Joint Pain) 07/2012 - 10/2008
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 01/2005
2	HIV Infections (HIV Infection) 01/2022 - 01/2005
2	Pain (Aches) 01/2021 - 10/2015
2	Basal Cell Nevus Syndrome (Gorlin Syndrome) 01/2020 - 11/2002
2	Autoimmune Diseases (Autoimmune Disease) 05/2016 - 12/2007
2	Thrombocytopenia (Thrombopenia) 07/2014 - 06/2009
2	Pruritus (Itching) 07/2014 - 02/2013
2	Inflammation (Inflammations) 01/2013 - 02/2010
2	Nausea 07/2012 - 06/2011
2	Hepatitis 07/2012 - 01/2010
2	Nevus (Nevi) 07/2012 - 01/2002
2	Renal Cell Carcinoma (Grawitz Tumor) 09/2008 - 07/2008
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Infections 01/2022
1	COVID-19 01/2021

Drug/Important Bio-Agent (IBA)

22	IpilimumabIBA 04/2022 - 10/2010
17	dabrafenibIBA 01/2020 - 07/2012
16	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2014
16	VemurafenibIBA 11/2021 - 06/2011
14	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 02/2003
13	Immune Checkpoint InhibitorsIBA 04/2022 - 01/2016
13	trametinibIBA 01/2020 - 11/2014
13	Interferon-alpha (Interferon Alfa)IBA 02/2013 - 08/2003
12	InterferonsIBA 05/2018 - 07/2008
11	Biomarkers (Surrogate Marker)IBA 04/2022 - 03/2012
11	Pharmaceutical PreparationsIBA 01/2022 - 01/2005
11	HhAntag691IBA 01/2019 - 06/2012
9	pembrolizumabIBA 04/2022 - 01/2015
9	Interferon alpha-2 (Roferon-A)FDA Link 08/2021 - 08/2003
9	Phosphotransferases (Kinase)IBA 01/2020 - 07/2008
8	Monoclonal AntibodiesIBA 01/2020 - 02/2010
7	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 06/2020 - 12/2007
7	AntibodiesIBA 01/2018 - 10/2010
6	Interleukin-2 (IL2)IBA 09/2019 - 08/2003
5	cemiplimabIBA 01/2021 - 01/2018
5	Biological ProductsIBA 01/2018 - 12/2008
5	Sorafenib (BAY 43-9006)FDA Link 09/2013 - 04/2007
5	tremelimumabIBA 02/2013 - 02/2010
4	Mitogen-Activated Protein KinasesIBA 03/2019 - 01/2014
4	Proto-Oncogene Proteins B-rafIBA 01/2017 - 06/2011
4	Paclitaxel (Taxol)FDA LinkGeneric 07/2014 - 10/2003
3	NivolumabIBA 04/2022 - 01/2015
3	cobimetinibIBA 01/2020 - 01/2019
3	Proteins (Proteins, Gene)FDA Link 09/2019 - 01/2014
3	Programmed Cell Death 1 ReceptorIBA 07/2018 - 01/2015
3	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2010 - 10/2005
2	Dihydrotachysterol (AT 10)IBA 11/2022 - 01/2020
2	PlacebosIBA 01/2020 - 01/2019
2	sonidegibIBA 01/2020 - 10/2016
2	binimetinibIBA 03/2019 - 03/2013
2	AcidsIBA 01/2019 - 02/2009
2	talimogene laherparepvecIBA 01/2019 - 10/2018
2	LigandsIBA 07/2018 - 01/2015
2	TropomyosinIBA 07/2018 - 11/2017
2	Creatine Kinase (Creatine Phosphokinase)IBA 01/2017 - 03/2013
2	S100 Calcium Binding Protein beta SubunitIBA 01/2016 - 02/2009
2	Histone Deacetylase InhibitorsIBA 06/2015 - 08/2008
2	elesclomolIBA 02/2015 - 03/2013
2	Temozolomide (Temodar)FDA LinkGeneric 02/2013 - 06/2009
2	peginterferon alfa-2b (Pegintron)FDA Link 01/2013 - 07/2008
2	Cisplatin (Platino)FDA LinkGeneric 12/2011 - 02/2003
2	Vindesine (Vindesin)IBA 12/2011 - 10/2008
2	Carboplatin (JM8)FDA LinkGeneric 06/2009 - 10/2003
2	liposomal doxorubicin (Doxil)FDA Link 04/2008 - 09/2003
2	Imiquimod (Aldara)FDA LinkGeneric 01/2005 - 11/2002
1	relatlimabIBA 04/2022
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021

Therapy/Procedure

78	Therapeutics 04/2022 - 02/2003
18	Drug Therapy (Chemotherapy) 04/2022 - 02/2003
13	Immunotherapy 04/2022 - 12/2008
6	Radiotherapy 01/2020 - 02/2008
3	Aftercare (After-Treatment) 01/2016 - 10/2009
3	Palliative Care (Palliative Therapy) 12/2015 - 01/2007
3	Duration of Therapy 01/2014 - 07/2008
3	Lymph Node Excision (Lymph Node Dissection) 08/2013 - 02/2008
3	Photochemotherapy (Photodynamic Therapy) 01/2010 - 10/2005
2	Injections 10/2018 - 02/2003
2	General Anesthesia 09/2006 - 01/2002
1	Organ Transplantation 01/2022